3SBio Inc - Asset Resilience Ratio

Latest as of December 2025: 10.64%

3SBio Inc (83B) has an Asset Resilience Ratio of 10.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 83B working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€3.86 Billion

≈ $4.51 Billion USD Cash + Short-term Investments

Total Assets

€36.25 Billion

≈ $42.38 Billion USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how 3SBio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 3SBio Inc total assets.

Liquid Assets Composition Over Time

This chart breaks down 3SBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 3SBio Inc (83B) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€3.86 Billion	10.64%
Total Liquid Assets	€3.86 Billion	10.64%

Asset Resilience Insights

Moderate Liquidity: 3SBio Inc has 10.64% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

3SBio Inc Industry Peers by Asset Resilience Ratio

Compare 3SBio Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	2.58%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Kailera Therapeutics, Inc. Common Stock NASDAQ:KLRA	Biotechnology	64.92%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	78.22%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%

Annual Asset Resilience Ratio for 3SBio Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for 3SBio Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.64%	€3.86 Billion ≈ $4.51 Billion	€36.25 Billion ≈ $42.38 Billion	-4.93pp
2024-12-31	15.57%	€3.77 Billion ≈ $4.41 Billion	€24.21 Billion ≈ $28.31 Billion	+1.59pp
2023-12-31	13.98%	€3.30 Billion ≈ $3.86 Billion	€23.63 Billion ≈ $27.62 Billion	-8.13pp
2022-12-31	22.11%	€4.86 Billion ≈ $5.68 Billion	€21.99 Billion ≈ $25.71 Billion	+12.22pp
2021-12-31	9.89%	€1.90 Billion ≈ $2.22 Billion	€19.21 Billion ≈ $22.46 Billion	+2.69pp
2020-12-31	7.20%	€1.27 Billion ≈ $1.49 Billion	€17.68 Billion ≈ $20.67 Billion	+4.01pp
2019-12-31	3.19%	€472.16 Million ≈ $552.01 Million	€14.81 Billion ≈ $17.31 Billion	+2.70pp
2018-12-31	0.49%	€68.13 Million ≈ $79.65 Million	€13.84 Billion ≈ $16.18 Billion	-4.63pp
2017-12-31	5.12%	€704.56 Million ≈ $823.71 Million	€13.75 Billion ≈ $16.08 Billion	+1.84pp
2016-12-31	3.28%	€362.17 Million ≈ $423.42 Million	€11.04 Billion ≈ $12.91 Billion	--

pp = percentage points

About 3SBio Inc

F:83B Germany Biotechnology

Market Cap

$5.09 Billion

€4.35 Billion EUR

Market Cap Rank

#3514 Global

#652 in Germany

Share Price

€1.74

Change (1 day)

-1.39%

52-Week Range

€1.63 - €3.68

All Time High

€3.88